The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats

Growth Hormone and IGF Research

Volumn 22, Issue 1, 2012, Pages 30-35

  Zhang, Zhi Xin ^a   Liu, Ying Ke ^a   Pan, Hui ^b   Pan, Lin ^a   Zhang, Qiong ^a   Su, Hui Min ^c   Zhao, Qiu Ling ^a   Li, Hong ^a   He, Chun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c Chaoyang Maternal and Child Care Service Centre   (China)

Author keywords

GH; Glucose metabolism; Growth; Hypophysectomize; IGF I; Polyethylene glycol

Indexed keywords

GROWTH HORMONE; INSULIN; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE GROWTH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HYPOPHYSECTOMY; INFUSION RATE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADIPONECTIN; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; BODY SIZE; BODY WEIGHT; BONE DEVELOPMENT; GLUCOSE CLAMP TECHNIQUE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HYPOPHYSECTOMY; INSULIN-LIKE GROWTH FACTOR I; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TAIL;

EID: 84862828651     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.12.002     Document Type: Article

References (45)

1. Chrisoulidou A., Beshyah S.A., Rutherford O., Spinks T.J., Mayet J., Kyd P. Effects of 7years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 2000, 85:3762-3769.
2. Bramnert M., Segerlantz M., Laurila E., Daugaard J.R., Manhem P., Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J. Clin. Endocrinol. Metab. 2003, 88:1455-1463.
3. Groop L., Segerlantz M., Bramnert M. Insulin sensitivity in adults with growth hormone deficiency and effect of growth hormone treatment. Horm. Res. 2005, 64(Suppl 3):45-50.
4. Hou C.W., Chou S.W., Ho H.Y., Lee W.C., Lin C.H., Kuo C.H. Interactive effect of exercise training and growth hormone administration on glucose tolerance and muscle GLUT4 protein expression in rats. J. Biomed. Sci. 2003, 10:689-696.
5. Hamidi M., Azadi A., Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006, 13:399-409.
6. Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 2007, 35:9-16.
7. Xu Yanping, Ke Huang, Liang Li, Wang Xiumin, Pei Jin, Du Lizhong PEG-rhGH therapy for small for gestational age rats and effects on their metabolic parameters. Horm Res Paediatr. 2011, 76(1):35-43.
8. Touraine P., D'Souza G.A., Kourides I., Abs R., Barclay P., Xie R. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur. J. Endocrinol. 2009, 161:533-540.
9. Webster R., Xie R., Didier E., Finn R., Finnessy J., Edgington A. PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. Xenobiotica 2008, 38:1340-1351.
10. Kim I., Kim T.H., Ma K., Lee E.S., Kim D., Oh K.T., et al. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug. Chem. 2010, 21(8):1513-1519.
11. Youn Y.S., Jeon J.E., Chae S.Y., Lee S., Lee K.C. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Diab. Nutr. Metab. 2008, 10(4):343-346.
12. Pan L., Du R.Q., Li H.L., Yang W.Y., Li G.W. Basic Clin. Med. 2008, 28(7):760-764.
13. Rasmussen M.H., Bysted B.V., Anderson T.W., Klitgaard T., Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J. Clin. Endocrinol. Metab. 2010, 95(7):3411-3417.
14. Møller N., Jørgensen J.O., Schmitz O., Møller J., Christiansen J., Alberti K.G. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am. J. Physiol. 1990, 258:E86-E91.
15. Giavoli C., Porretti S., Ronchi C.L., Cappiello V., Ferrante E., Orsi E. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004, 53:740-743.
16. Hansen I., Tsalikian E., Beaufrere B., Gerich J., Haymond M., Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am. J. Physiol. 1986, 250:E269-E273.
17. Yuen K., Ong K., Husbands S., Chatelain P., Fryklund L., Gluckman P. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults. J. Clin. Endocrinol. Metab. 2002, 87:1989-1995.
18. Fowelin J., Attvall S., Lager I., Bengtsson B.A. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993, 42:1443-1447.
19. Bak J.F., Moller N., Schmitz O. Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans. Am. J. Physiol. 1991, 260:E736-E742.
20. Hew F.L., Koschmann M., Christopher M., Rantzau C., Vaag A., Ward G. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. 1996, 81:555-564.
21. Muniyappa R., Chen H., Muzumdar R., Einstein F.H., Yan X., Yue L.Q. Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats. Am. J. Physiol. Endocrinol. Metab. 2009, 8:E1023.
22. Neal D.N., Kalfas A., Dunning P.L., Christopher M.J., Sawyer S.D., Ward G.M., et al. The effect of 3 months treatment of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults. J. Clin. Endocrinol. Metab. 2007, 79(4):975-983.
23. Yuen K., Cook D., Ong K., Chatelain P., Fryklund L., Gluckman P. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin. Endocrinol. (Oxf) 2002, 57:333-341.
24. Jessen N., Djurhuus C.B., Jørgensen J.O., Jensen L.S., Møller N., Lund S. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E194-E199.
25. Yuen K., Wareham N., Frystyk J., Hennings S., Mitchell J., Fryklund L. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur. J. Endocrinol. 2004, 151:39-45.
26. Yuen K., Frystyk J., Umpleby M., Fryklund L., Dunger D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J. Clin. Endocrinol. Metab. 2004, 89:3956-3964.
27. Sas T.C., de Muinck Keizer-Schrama S.M., Stijnen T., Aanstoot H.J., Drop S.L. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J. Clin. Endocrinol. Metab. 2000, 85:769-775.
28. Hokken-Koelega A.C., Sas T., van Pareren Y. Effects of long-term GH treatment on insulin sensitivity and glucose tolerance. J. Pediatr. Endocrinol. Metab. 2002, 15(Suppl 5):1277-1278.
29. Arafat A.M., Möhlig M., Weickert M.O., Schöfl C., Spranger J., Pfeiffer A.F. Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study. Diabetologia 2010, 53(7):1304-1313.
30. Arwert L.I., Roos J.C., Lips P., Twisk J.W., Manoliu R.A., Drent M.L. Effects of 10years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin. Endocrinol. (Oxf) 2005, 63:310-316.
31. Hana V., Silha J.V., Justova V., Lacinova Z., Stepan J.J., Murphy L.J. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin. Endocrinol. (Oxf) 2004, 60:442-450.
32. Yuen K.C., Frystyk J., White D.K., Twickler T.B., Koppeschaar H.P., Harris P.E. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin. Endocrinol. (Oxf) 2005, 63:428-436.
33. Yuen K.C., Dunger D.B. Persisting effects on fasting glucose levels and insulin sensitivity after 6months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency. Clin. Endocrinol. (Oxf) 2006, 64:549-555.
34. Sesti G., Sciacqua A., Cardellini M., Marini M.A., Maio R., Vatrano M. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005, 28:120-125.
35. Sandhu M.S., Heald A.H., Gibson J.M., Cruickshank J.K., Dunger D.B., Wareham N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002, 359:1740-1745.
36. Yuen K.C., Dunger D.B. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diab. Obes. Metab. 2007, 9:11-22.
37. Kulkarni R.N., Holzenberger M., Shih D.Q., Ozcan U., Stoffel M., Magnuson M.A. Beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat. Genet. 2002, 31:111-115.
38. Kulkarni R.N., Holzenberger M., Shih D.Q., Ozcan U., Stoffel M., Magnuson M.A. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J. Clin. Invest. 2002, 110:1011-1019.
39. Liu W., Chin-Chance C., Lee E.J., Lowe W.L. Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death. Endocrinology 2002, 143:3802-3812.
40. Spranger J., Kroke A., Möhlig M., Bergmann M.M., Ristow M., Boeing H. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
41. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
42. Schmid C., Bianda T., Zwimpfer C., Zapf J., Wiesli P. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels. Growth Horm. IGF Res. 2005, 15:300-303.
43. Lam K.S., Xu A., Tan K.C., Wong L.C., Tiu S.C., Tam S. Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J. Clin. Endocrinol. Metab. 2004, 89:5448-5453.
44. Joaquin C., Aguilera E., Granada M.L., Pastor M.C., Salinas I., Alonso N. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 2008, 158:483-490.
45. Edén Engström B., Burman P., Holdstock C., Karlsson F.A. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J. Clin. Endocrinol. Metab. 2003, 88:5193-5198.